Vaccines Day for investors was on June 4, 2008, in Cambridge, Mass.
| About Novartis Vaccines | Products | Pipeline | Press Room | Locations |
Latest News
Welcome to the Novartis Vaccines Press Room. You can find copies of our latest press releases, Novartis Vaccines links, contact information and general details about the Novartis Vaccines business unit. Our team of international communications professionals is always available to help meet the information needs of the news media around the world. We hope that you find these materials useful and encourage you to contact us directly if further details are required. Thank you for your interest in Novartis Vaccines.
For further information please do not hesitate to contact us.
20-June-2008
Novartis Vaccines continue to be poised for growth. Investment of €145 million by Novartis Vaccines is among the greatest in the Germany. Increasing need for vaccines to prevent rabies and tick borne encephalitis calls for new facility
04-June-2008
Novartis presents full pipeline of novel vaccines addressing significant unmet needs
Novartis unveiled today a promising pipeline of novel vaccines, highlighting vaccine candidates that address significant unmet needs for prevention of fatal diseases such as meningococcal infections and other hospital and community acquired infections. Several vaccine candidates from the Novartis Vaccines research and development portfolio have the potential of being first of its kind.
14-May-2008
New data for the investigational recombinant meningococcal group B vaccine developed by Novartis Vaccines, support its promise as the first potentially broad coverage vaccine capable of protecting infants against the meningococcal B strain. Prevention of meningococcal B infections remains a high medical need to protect infants and children worldwide from infection of this often deadly disease.
06-May-2008
New Phase III data for Menveo® (MenACWY-CRM) show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Menactra®. Infection with any of these four vaccine-preventable serogroups can lead to bacterial meningitis, an infection of the membrane around the brain and spinal cord, or sepsis, a serious infection of the blood stream.
09-January-2008
Menveo(TM) (MenACWY-CRM), a vaccine in development by Novartis, may protect infants using a schedule beginning at two months of age against four of the most common causes of meningococcal disease. Menveo is the only meningococcal vaccine shown to generate protection against a broad range of serogroups in infants, potentially filling a large unmet medical need.
15-November-2007
New clinical data for the Novartis development vaccine Menveo(TM) [2] (MenACWY-CRM) show an excellent and broad immune response in infants as young as six months of age against four common serogroups (or types) of meningococcal meningitis, a potentially fatal bacterial disease involving inflammation of membranes around the brain and spinal cord.
19-October-2007
Vaccinating elderly subjects with an MF59™-adjuvanted seasonal influenza vaccine (Fluad® from Novartis) resulted in a significant reduction in hospitalization for major conditions such as pneumonia, acute coronary syndrome (ACS) and cerebrovascular accident (CVA) during the influenza season. Data published in this week’s international journal Vaccine illustrate the positive outcomes provided by an adjuvanted seasonal influenza vaccine.
23-August-2007
Novartis broke ground today on construction of the first cell culture-derived influenza vaccines manufacturing plant in the United States. Once completed, the facility is expected to have an annual production capacity of up to 50 million doses of seasonal trivalent flu vaccine.
16-August-2007
Novartis announced today the availability in the US of the first shipments of Fluvirin® influenza virus vaccine for the 2007/08 season.
03-July-2007
Novartis Vaccines, the second largest supplier of influenza vaccines in the US, plans to produce approximately 40 million doses of its Fluvirin® vaccine for distribution in the US during the upcoming 2007/08 influenza season - a 30% increase in supply from Novartis compared to the previous influenza season.
03-July-2007
Novartis Vaccines, the second largest supplier of influenza vaccines in the US, plans to produce approximately 40 million doses of its Fluvirin® vaccine for distribution in the US during the upcoming 2007/08 influenza season - a 30% increase in supply from Novartis compared to the previous influenza season.
02-July-2007
Novartis and Intercell AG have formed one of the vaccines industry's most comprehensive and innovative strategic alliances, combining the research, development, manufacturing and commercialization capabilities of Novartis with Intercell's unique research skills and highly-respected pipeline.
13-June-2007
Novartis gains European approval for its innovative flu vaccine Optaflu®
Optaflu®, the first influenza vaccine to utilize a Novartis proprietary cell line for the production of viral antigen components rather than the traditional chicken eggs, has received European Union approval in all 27 member states, as well as Iceland and Norway.
08-May-2007
Focetria®, the Novartis pandemic influenza vaccine, receives European Union approval
Focetria®, a new human vaccine designed for use following the declaration of an influenza pandemic, has received European Union approval in all 27 member states as well as Iceland and Norway.
27-APR-2007
Novartis has received a positive opinion supporting European Union approval of its cell culture-derived seasonal influenza vaccine Optaflu®, which is aiming to become the first influenza vaccine to utilize a mammalian cell line, rather than chicken eggs, for antigen production.
23-FEB-2007
Novartis announced today that it has received a positive opinion supporting European Union regulatory approval of the human vaccine Focetria® for use in the event of an pandemic influenza outbreak, such as one that could be caused by the H5N1 virus.
17-JAN-2007
Novartis announced that it has received a contract from the US Department of Health and Human Services (HHS) of approximately USD 55 million. The contract supports the company’s efforts to bring the antigen-sparing capabilities of the MF59 adjuvant to the United States. An adjuvant is a substance added to a vaccine to enhance the body’s immune response to the vaccine’s active constituent, called the antigen.
14-DEC-2006
Novartis has made significant progress in creating a new strategic growth platform in human vaccines, announcing today the division’s new global headquarters location in Cambridge, Massachusetts, and that more than 30 million doses of flu vaccines will be shipped to the US for the current influenza season.
28-NOV-2006
Novartis announced today that the European Medicines Agency (EMEA) has accepted for review the company’s application for an MF59-adjuvanted pre-pandemic H5N1 influenza vaccine. Novartis’ adjuvanted H5N1 vaccine is the first vaccine being evaluated for the prevention of infections from avian influenza (also known as “bird flu”) in four clinical studies.
20-NOV-2006
Novartis secures contract to supply additional H5N1 influenza vaccine to the US government
Novartis announced today that it has been awarded a contract valued at USD 40.95 million to supply to the US government a pre-pandemic influenza vaccine* against the H5N1 avian influenza strain. Global health authorities have identified H5N1 as an influenza strain with pandemic potential.
16-NOV-2006
Novartis announced today that the final results of the pivotal Phase III trial for the Japanese Encephalitis vaccine (IC51) were presented at the annual meeting of the American Society of Topical Medicine and Hygiene (ASTMH) in Atlanta.
19-OCT-2006
Novartis announced today data demonstrating the protective benefits conferred by MF59-adjuvanted influenza vaccine (FLUAD) in adults with chronic diseases, at higher risk of post-influenza complications.
19-OCT-2006
Novartis announced today results of pivotal Phase III clinical trial data for its innovative cell culture-derived influenza vaccine demonstrating that it is highly capable of producing an immune response (“immunogenic”), one at least as strong as the traditional egg-derived influenza vaccine Aggripal® for each of the three influenza strains studied.
16-AUG-2006
Novartis releases Fluvirin® influenza virus vaccine to US distributors
Novartis announced today the delivery and release of its first shipments of Fluvirin® influenza virus vaccine to the United States for the 2006-2007 influenza season, with continued shipments expected to follow through the end of the year.
08-AUG-2006
Novartis announced today the successful conclusion of a two-year nationwide mass vaccination campaign in New Zealand based on the company's MeNZB(TM) vaccine, which was developed specifically for the effort.
18-JUL-2006
Novartis to build latest-technology influenza vaccines manufacturing site in North Carolina
Novartis announced today plans to build the first cell culture-derived influenza vaccines manufacturing plant in the United States at a site in Holly Springs, North Carolina, with construction expected to begin in 2007.
13-JUN-2006
Novartis announced today the expansion of its late-stage vaccines pipeline through an agreement to acquire marketing and distribution rights for IC51, a vaccine in Phase III clinical trials for the prevention of infections from the Japanese Encephalitis virus.
04-MAY-2006
Novartis announced today that the US Department of Health and Human Services (HHS) has awarded Novartis Vaccines up to USD 220 million to support the development of a cell culture-derived influenza vaccine, both to supply seasonal influenza vaccine and to respond rapidly in the event of an influenza pandemic.
19-APR-2006
Novartis acquisition of Chiron approved by Chiron shareholders
Novartis announced today that shareholders of Chiron Corporation voted to approve its acquisition of Chiron, paving the way for the creation of a new division at Novartis focusing on vaccines and diagnostics.
    |
  |
  |
Vaccines Day
Multimedia Press Room
Visit the Novartis Vaccines & Diagnostics Multimedia Press Room for broadcast standard video, print and other multimedia files.
About Novartis
We provide medicines to treat and prevent diseases, ease suffering and improve quality of life.